| Line | All comers | Risk group |
|---|
| Screening, prevention and diagnosis | 1 | · |
| Early / localised | · | 1 |
| Advanced, first line | 1 | · |
| Second line | 1 | · |
| Other settings | 2 | · |
Screening, prevention and diagnosis
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Staging | Pelvic MRI and whole-body PET-CT; surgical para-aortic staging in selected cases. | | | 92 |
Early / localised
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| Risk group | High-risk disease (node-positive IB2 to IIB, III to IVA) | Pembrolizumab with chemoradiation and for up to two years afterwards (KEYNOTE-A18). | | | 98 |
Advanced, first line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Induction option | Six weekly cycles of carboplatin-paclitaxel before chemoradiation (INTERLACE), particularly where immunotherapy is not available. | | | 87 |
Second line
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Central pelvic recurrence after radiotherapy | Pelvic exenteration in selected patients; re-irradiation with brachytherapy or protons in specialist centres. | | | 40 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|
| All comers | Standard chemoradiation | Weekly cisplatin with pelvic external-beam radiotherapy followed by image-guided brachytherapy, completed within eight weeks. | | | 93 |
| All comers | Not recommended | Adjuvant carboplatin-paclitaxel after chemoradiation gave no benefit in OUTBACK. | | | 82 |
Sequence and caution pairings
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.